智通财经APP获悉，据港交所9月29日披露，四川百利天恒药业股份有限公司(简称：百利天恒)向港交所主板提交上市申请 书，高盛、摩根大通、中信证券为其联席保荐人。百利天恒(688506.SH)已经在上交所上市。 据招股书，百利天恒是一家聚焦全球生物医药前沿领域，立足于解决未被满足的临床需求，在肿瘤大分子治疗领域 (ADC/GNC/ARC)具备全球领先的创新研发能力、全球临床开发和规模化生产供应能力，并将在2029年形成全球商业化能力 的综合性生物医药企业。公司致力成为在肿瘤用药领域持续保持全球领先地位的跨国药企(MNC)，经营两项主要业务（创 新生物药业务以及仿制药及中成药业务）。 2014年百利天恒在美国西雅图创建了SystImmune、并开始研发iza-bren (BL-B01D1)，为全球首创且迄今唯一一款进入III期 临床开发的EGFR×HER3双特异性 ADC。2024年，百利天恒与BMS就iza-bren达成了总额84亿美元、首付8亿美元、迄今为 止全球ADC领域单个资产总交易额最大的全球战略许可及合作交易。 百利天恒在美国的十年努力，不仅构建起了创新ADC药物研发平台，成功研发包括iza-bren ...

截至2025年6月30日，药明生物一体化平台上的临床III期及商业化生产项目分别达67和24个，收益同比 增24.9%。此外，其研究服务已经赋能50多个分子项目，并有权益收取未来的潜在里程碑付款和销售提 成，将显著提升公司长期利润增长。其为GSK开发的一款分子已进入临床阶段，成为药明生物赋能的第 四个进入临床阶段的TCE项目。 项目订单方面，药明生物未完成订单总额超200亿美元，达203.4亿美元。3年内未完成订单总额增长至 42.1亿美元，近期收入预期增长可观。 药明生物(02269)2025年中期业绩发布，上半年新签综合项目86个，创同期历史新高，推高综合项目总 数至864个，进一步巩固其拥有业界最大的复杂生物药产品线之一的领先地位。新签项目中，双抗多 抗、ADC占比超70%，引领创新生物药两大黄金赛道。业绩快速增长支撑药明生物上调2025全年收入指 引至14%-16%。 ...

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Zhuhai Tenomab Pharmaceutical Co., Ltd. (Tenomab) has applied for a change in its listing review status on the Shanghai Stock Exchange's Sci-Tech Innovation Board to "inquired," with plans to raise 1.5 billion RMB [1] Company Overview - Tenomab is an innovative biopharmaceutical company focused on blood product alternatives, equipped with proprietary technology platforms for monoclonal antibody development and production [1] - The company has developed several core technology platforms, including HitmAb® for high-throughput human monoclonal antibody research and a CHO-GS cell platform for efficient antibody expression [1] Key Products - The core product, TNM002 (Stadotamab Injection), is a first-in-class recombinant human monoclonal antibody for tetanus prevention, expected to be approved in China by February 2025 and recognized as a breakthrough therapy by the CDE [2] - Another key product, TNM001, is a potential third global and first domestic long-acting monoclonal antibody for RSV prevention in infants, currently undergoing Phase III clinical trials [2] Fundraising and Investment Plans - The total investment for the new drug development project is approximately 836.5 million RMB, with 830 million RMB planned to be raised from this issuance [3] - The antibody production base expansion project has a total investment of about 381.37 million RMB, with 330 million RMB from the raised funds [3] - The company plans to allocate all raised funds to its main business projects and operational needs [2][3] Financial Performance - In 2022, the company reported revenues of approximately 4.34 million RMB, with projected revenues of 15.06 million RMB in 2024 and 1.69 million RMB in Q1 2025 [3] - The net profit for 2022 was approximately -429 million RMB, with projected losses of -446 million RMB in 2023 and -515 million RMB in 2024 [3] - As of March 31, 2025, total assets are reported at approximately 1.13 billion RMB, with a debt-to-asset ratio of 56.48% [4]

四川百利天恒药业股份有限公司 上市公告书 股票简称：百利天恒 股票代码：688506 四川百利天恒药业股份有限公司 上市公告书 特别提示 四川百利天恒药业股份有限公司（以下简称"百利天恒"、"发行人"、"公 司"或"本公司"）股票将于 2023 年 1 月 6 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上 市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 四川百利天恒药业股份有限公司 （成都市温江区成都海峡两岸科技产业园百利路 161 号一幢一号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （广东省深圳市福田区福田街道福华一路 119 号安信金融大厦） 二〇二三年一月五日 1 四川百利天恒药业股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所（以下简称"上交所"）、有关政府机关对本公司股票上市 及有关事项的意见，均不表明对本公司的任何保证。 本 公 司 ...